Vaccines for post-exposure prophylaxis against varicella (chickenpox) in children and adults

Cochrane Database of Systematic Reviews

Volumn , Issue 3, 2008, Pages

  Macartney, Kristine ^a   McIntyre, Peter ^b  

^a CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CHICKENPOX VACCINE; PLACEBO; VARICELLA ZOSTER VACCINE;

CHICKENPOX; CLINICAL TRIAL; COCHRANE LIBRARY; DRUG EFFICACY; DRUG SAFETY; EMBASE; FEVER; HUMAN; INJECTION SITE REACTION; MEDLINE; PROPHYLAXIS; RASH; REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VACCINATION;

EID: 55049128593     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD001833.pub2     Document Type: Review

References (186)

1. Arbeter 1986a {published data only} Arbeter AM, Starr SE, Weibel RE, Plotkin SA. Varicella vaccine studies in healthy children and adults. Pediatrics 1986;78(Suppl):748-56.
2. Asano 1977a {published data only} Asano Y, Nakayama H, Yazaki T, Kato R, Hirose S. Protection against varicella in family contacts by immediate inoculation with live varicella vaccine. Pediatrics 1977;59:3-7.
3. Mor 2004 {published data only} Mor M, Harel L, Kahan E, Amir J. Efficacy of postexposure immunization with live attenuated varicella vaccine in the household setting - a pilot study. Vaccine 2004;23:325-8.
4. Alpay 2002 {published data only} Alpay H, Yildiz N, Onar A, Temizer H, Ozcay S. Varicella vaccination in children with steroid-sensitive nephrotic syndrome. Pediatric Nephrology 2002;17:181-3.
5. Ampofo 2002 {published data only} Ampofo K, Saiman L, LaRussa P, Steinberg S, Annunziato P, Gershon A. Persistence of immunity to live attenuated varicella vaccine in healthy adults. Clinical Infectious Diseases 2002;34:774-9.
6. Arbeter 1982 {published data only} Arbeter AM, Starr SE, Weibel RE, Plotkin SA. Live attenuated varicella vaccine: immunization of healthy children with the OKA strain. Journal of Pediatrics 1982;100:886-93.
7. Arbeter 1983 {published data only} Arbeter AM, Starr SE, Weibel RE, Neff BJ, Plotkin SA. Live attenuated varicella vaccine: the KMcC strain in healthy children. Pediatrics 1983;71(3):307-12.
8. Arbeter 1984 {published data only} Arbeter AM, Starr SE, Preblud SR, Ihara T, Paciorek PM, Miller DS, et al.Varicella vaccine trials in healthy children. A summary of comparative and follow-up studies. American Journal of Diseases of Children 1984;138:434-8.
9. Arbeter 1986b {published data only} Arbeter AM, Starr SE, Plotkin SA. Varicella vaccine studies in healthy children and adults. Pediatrics 1986;78:748-56.
10. Arbeter 1986c {published data only} Arbeter AM, Starr SE, Plotkin SA. Varicella vaccine studies in healthy children and adults. Pediatrics 1986;78(4 Pt 2):748-56.
11. Arbeter 1990 {published data only} Arbeter AM, Granowetter L, Starr SE, Lange B, Wimmer R, Plotkin SA. Immunization of children with acute lymphoblastic leukemia with live attenuated varicella vaccine without complete suspension of chemotherapy. Pediatrics 1990;85(3):338-44.
12. Asano 1975 {published data only} Asano Y, Yazaki T, Miyata T, Nakayama H, Hirose S. Application of a live attenuated varicella vaccine to hospitalized children and its protective effect on spread of varicella infection. Biken Journal 1975;18:35-40.
13. Asano 1977b {published data only} * Asano Y, Takahashi M. Clinical and serologic testing of a live varicella vaccine and two-year follow-up for immunity of the vaccinated children. Pediatrics 1977;60:810-4.
14. Asano 1977c {published data only} Asano Y, Nakayama H, Yazaki T, Ito S, Isomura S. Protective efficacy of vaccination in children in four episodes of natural varicella and zoster in the ward. Pediatrics 1977;59:8-12.
15. Asano 1982 {published data only} * Asano Y, Hirose S, Iwayama S, Miyata T, Yazaki T, Takahashi M. Protective effect of immediate inoculation of a live varicella vaccine in household contacts in relation to the viral dose and interval between exposure and vaccination. Biken Journal 1982;25:43-5.
16. Asano 1983 {published data only} Asano Y, Albrecht P, Vujcic LK, Quinnan GV, Jr, Kawakami K, Takahashi M. Five-year follow-up study of recipients of live varicella vaccine using enhanced neutralization and fluorescent antibody membrane antigen assays. Pediatrics 1983;72(3):291-4.
17. Asano 1984 {published data only} Asano Y, Nagai T, Miyata T, Yazaki T, Ito S, Yamanishi K, et al.Persistence of protective immunity after inoculation with live varicella vaccine (strain Oka). Biken Journal 1984;27:123-8.
18. Asano 1985 {published data only} Asano Y, Nagai T, Miyata T, Yazaki T, Ito S, Yamanishi K, et al.Long-term protective immunity of recipients of the OKA strain of live varicella vaccine. Pediatrics 1985;75(4):667-71.
19. Asano 1994 {published data only} Asano Y, Suga S, Yoshikawa T, Kobayashi I, Yazaki T, Shibata M, et al.Experience and reason: twenty-year follow-up of protective immunity of the Oka strain live varicella vaccine. Pediatrics 1994;94:524-6.
20. Bancillon 1991 {published data only} Bancillon A, Leblanc T, Baruchel A, Schaison G, Leverger G, Mallarmey D, et al.Study of tolerance and effectiveness of a varicella vaccine in leukemic children. Nouvelle Revue Francaise d'Hematologie 1991;33:555-6.
21. Bednarek 2004 {published data only} Bednarek M, Majda-Stanislawska E. Varicella vaccination safety in children with allergy. Pediatria Polska 2004;79:27-31.
22. Bekker 2006 {published data only} Bekker V, Westerlaken GHA, Scherpbier H, Alders S, Zaaijer H, Van BD, et al.Varicella vaccination in HIV-1-infected children after immune reconstitution. AIDS 2006;20(18):2321-9.
23. Bergen 1990 {published data only} Bergen RE, Diaz PS, Arvin AM. The immunogenicity of the Oka/Merck varicella vaccine in relation to infectious varicella-zoster virus and relative viral antigen content. Journal of Infectious Diseases 1990;162:1049-54.
24. Berger 1984 {published data only} Berger R, Luescher D, Just M. Enhancement of varicella-zoster-specific immune responses in the elderly by boosting with varicella vaccine. Journal of Infectious Diseases 1984;149(4):647.
25. Berger 1985 {published data only} Berger R, Amstutz I, Just M, Just V, Luescher D. Booster vaccination of healthy adults with VZV antibody but without a VZV-specific cell-mediated immune response. Antiviral Research 1985;Suppl 1:267-71.
26. Berger 1998 {published data only} Berger R, Trannoy E, Hollander G, Bailleux F, Rudin C, Creusvaux H. A dose-response study of a live attenuated varicella-zoster virus (Oka strain) vaccine administered to adults 55 years of age and older. Journal of Infectious Diseases 1998;178(Suppl 1):99-103.
27. Bernstein 1993 {published data only} Bernstein HH, Rothstein EP, Watson BM, Reisinger KS, Blatter MM, Wellman CO, et al.Clinical survey of natural varicella compared with breakthrough varicella after immunization with live attenuated Oka/Merck varicella vaccine. Pediatrics 1993;92:833-7.
28. Black 2006 {published data only} Black SB, Cimino CO, Hansen J, Lewis E, Ray P, Corsaro B, et al.Immunogenicity and safety of measles-mumps-rubella, varicella and Haemophilus influenzae type b vaccines administered concurrently with a fourth dose of heptavalent pneumococcal conjugate vaccine compared with the vaccines administered without heptavalent pneumococcal conjugate vaccine. Pediatric Infectious Disease Journal 2006;25(4):306-11.
29. Bogger-Goren 1982 {published data only} Bogger-Goren S, Baba K, Hurley P, Yabuuchi H, Takahashi M, Ogra PL. Antibody response to varicella-zoster virus after natural or vaccine-induced infection. Journal of Infectious Diseases 1982;146(2):260-5.
30. Broyer 1985 {published data only} Broyer M, Boudailliez B. Varicella vaccine in children with chronic renal insufficiency. Postgraduate Medical Journal 1985;61(Suppl 4):103-6.
31. Brunell 1982 {published data only} Brunell PA, Shehab Z, Geiser C, Waugh JE. Administration of live varicella vaccine to children wtih leukaemia. Lancet 1982;2(8307):1069-73.
32. Brunell 1986 {published data only} Brunell PA, Taylor-Wiedeman J, Geiser CF, Frierson L, Lydick E. Risk of herpes zoster in children with leukemia: varicella vaccine compared with history of chickenpox. Pediatrics 1986;77(1):53-6.
33. Brunell 1988 {published data only} Brunell PA, Novelli VM, Lipton SV, Pollock B. Combined vaccine against measles, mumps, rubella, and varicella. Pediatrics 1988;81:779-84.
34. Burgess 1999 {published data only} Burgess MA, Cossart YE, Wilkins TD, Botham S, Fearns G, Chitour K. Varicella vaccination of health-care workers. Vaccine 1999;17(7-8):765-9.
35. Clements 1995 {published data only} Clements DA, Armstrong CB, Ursano AM, Moggio MM, Walter EB, Wilfert CM. Over five-year follow-up of Oka/Merck varicella vaccine recipients in 465 infants and adolescents. Pediatric Infectious Disease Journal 1995;14:874-9.
36. Cristofani 1991 {published data only} Cristofani LM, Weinberg A, Peixoto V, et al.Administration of live attenuated varicella vaccine to children with cancer before starting chemotherapy. Vaccine 1991;9(12):873-6.
37. D'Angio 2007 {published data only} D'Angio CT, Boohene PA, Mowrer A, Audet S, Menegus MA, Schmid DS, et al.Measles-mumps-rubella and varicella vaccine responses in extremely preterm infants. Pediatrics 2007;119(3):574-9.
38. Davies 1994 {published data only} Davies J, Hallworth JA, McLeish P, Randall S, Martin BA, Buchan A, et al.Characterization and immunogenicity of a candidate subunit vaccine against varicella-zoster virus. Medical Microbiology & Immunology 1994;183(2):105-17.
39. Dennehy 1991 {published data only} Dennehy PH, Reisinger KS, Blatter MM, Veloudis BA. Immunogenicity of subcutaneous versus intramuscular Oka/Merck varicella vaccination in healthy children. Pediatrics 1991;88:604-7.
40. Dennehy 1994 {published data only} Dennehy PH, Saracen CL, Peter G. Seroconversion rates to combined measles-mumps-rubella-varicella vaccine of children with upper respiratory tract infection. Pediatrics 1994;94:514-6.
41. Diaz 1991 {published data only} Diaz PS, Au D, Smith S, Amylon M, Link M, Smith S, et al.Lack of transmission of the live attenuated varicella vaccine virus to immunocompromised children after immunization of their siblings. Pediatrics 1991;87(2):166-70.
42. Diaz 2006 {published data only} Diaz C, Dentico P, Gonzalez R, Mendez RG, Cinquetti S, Barben JL, et al.Safety, tolerability, and immunogenicity of a two-dose regimen of high-titer varicella vaccine in subjects > or =13 years of age. Vaccine 2006;24(47-8):6875-85.
43. Duchateau 1985 {published data only} Duchateau J, Vrijens R, Nicaise J, D'Hondt E, Bogearts H, Andre FE. Stimulation of specific immune response to varicella antigens in the elderly with varicella vaccine. Postgraduate Medical Journal 1985;61(Suppl 4):147-50.
44. Englund 1989 {published data only} Englund JA, Suarez CS, Kelly J, Tate DY, Balfour HH, Jr. Placebo-controlled trial of varicella vaccine given with or after measles-mumps-rubella vaccine. Journal of Pediatrics 1989;114:37-44.
45. Enright 2006 {published data only} Enright F, McMahon B, Washington A. Varicella outbreak in a residential home; A short report and literature review on postexposure prophylaxis. Irish Medical Journal 2006;99(5):133-5.
46. Fadrowski 2004 {published data only} Fadrowski JJ, Furth SL. Varicella zoster virus: vaccination and implications in children with renal failure. Expert Review of Vaccines 2004;3:291-8.
47. Furth 2003a {published data only} Furth SL, Hogg RJ, Tarver J, Moulton LH, Chan C, Fivush BA, et al.Varicella vaccination in children with chronic renal failure. A report of the Southwest Pediatric Nephrology Study Group. Pediatric Nephrology 2003;18:33-8.
48. Furth 2003b {published data only} Furth SL, Arbus GS, Hogg R, Tarver J, Chan C, Fivush BA, et al.Varicella vaccination in children with nephrotic syndrome: a report of the Southwest Pediatric Nephrology Study Group. Journal of Pediatrics 2003;142:145-8.
49. Gatchalian 2003 {published data only} Gatchalian S, Leboulleux D, Desauziers E, Bermal N, Borja-Tabora C. Immunogenicity and safety of a varicella vaccine, Okavax, and a trivalent measles, mumps and rubella vaccine, MMR-II, administered concomitantly in healthy Filipino children aged 12-24 months. Southeast Asian Journal of Tropical Medicine & Public Health 2003;34:589-97.
50. Gatchalian 2004 {published data only} Gatchalian S, Tabora C, Bermal N, Leboulleux D, Desauziers E. Immunogenicity and safety of a varicella vaccine (Okavax) and a trivalent measles, mumps, and rubella vaccine (Trimovax) administered concomitantly in healthy Filipino children 12-24 months old. American Journal of Tropical Medicine & Hygiene 2004;70:273-7.
51. Gershon 1982 {published data only} Gershon AA, Steinberg S, Borkowsky W. Clinical trial of live attenuated Varicella vaccine in high risk susceptibles - a preliminary report. Developments in Biological Standardization 1982;52:391-7.
52. Gershon 1984 {published data only} Gershon AA, Steinberg SP, Gelb L, Galasso G, Borkowsky W, LaRussa P, et al.Live attenuated varicella vaccine. Efficacy for children with leukemia in remission. JAMA 1984;252(3):355-62.
53. Gershon 1985 {published data only} Gershon AA, Steinberg S, Gelb L, Galasso G, Borkowsky W, LaRussa P, et al.A multicentre trial of live attenuated varicella vaccine in children with leukaemia in remission. Postgraduate Medical Journal 1985;61(Suppl 4):73-8.
54. Gershon 1986 {published data only} Gershon AA, Steinberg SP, Gelb L. Live attenuated varicella vaccine use in immunocompromised children and adults. Pediatrics 1986;78(4 Pt 2):757-62.
55. Gershon 1988 {published data only} Gershon AA, Steinberg SP, LaRussa P, Ferrara A, Hammerschlag M, Gelb L. Immunization of healthy adults with live attenuated varicella vaccine [Erratum appears in J Infect Dis 1988 Nov;158(5):1149]. Journal of Infectious Diseases 1988;158:132-7.
56. Gershon 1989 {published data only} Gershon AA, Steinberg SP. Persistence of immunity to varicella in children with leukemia immunized with live attenuated varicella vaccine. New England Journal of Medicine 1989;320:892-7.
57. Gershon 1990 {published data only} Gershon AA, Steinberg SP. Live attenuated varicella vaccine: protection in healthy adults compared with leukemic children. National Institute of Allergy and Infectious Diseases Varicella Vaccine Collaborative Study Group. Journal of Infectious Diseases 1990;161:661-6.
58. Giacchino 1995 {published data only} Giacchino R, Marcellini M, Timitilli A, Degli IL, Losurdo G, Palumbo M, et al.Varicella vaccine in children requiring renal or hepatic transplantation. Transplantation 1995;60:1055-6.
59. Guerra 2006 {published data only} Guerra FA, Gress J, Werzberger A, Reisinger K, Walter E, Lakkis H, et al.Safety, tolerability and immunogenicity of VAQTA given concomitantly versus nonconcomitantly with other pediatric vaccines in healthy 12-month-old children. Pediatric Infectious Disease Journal 2006;25(10):912-9.
60. Ha 1980 {published data only} Ha K, Baba K, Ikeda T, Nishida M, Yabuuchi H, Takahashi M. Application of live varicella vaccine to children with acute leukemia or other malignancies without suspension of anticancer therapy. Pediatrics 1980;65(2):346-50.
61. Habermehl 1999 {published data only} Habermehl P, Lignitz A, Knuf M, Schmitt HJ, Slaoui M, Zepp F. Cellular immune response of a varicella vaccine following simultaneous DTaP and VZV vaccination. Vaccine 1999;17(7-8):669-74.
62. Hardy 1991 {published data only} Hardy I, Gershon AA, Steinberg SP, LaRussa P. The incidence of zoster after immunization with live attenuated varicella vaccine. A study in children with leukemia. Varicella Vaccine Collaborative Study Group. New England Journal of Medicine 1991;325:1545-50.
63. Hata 2002 {published data only} * Hata A, Asanuma H, Rinki M, Sharp M, Wong RM, Blume K. Use of an inactivated varicella vaccine in recipients of hematopoietic-cell transplants. New England Journal of Medicine 2002;347:26-34.
64. Hayward 1992 {published data only} Hayward A, Villanueba E, Cosyns M, Levin M. Varicella-zoster virus (VZV)-specific cytotoxicity after immunization of nonimmune adults with Oka strain attenuated VZV vaccine. Journal of Infectious Diseases 1992;166:260-4.
65. Hayward 1994 {published data only} Hayward AR, Buda K, Levin MJ. Immune response to secondary immunization with live or inactivated VZV vaccine in elderly adults. Viral Immunology 1994;7:31-6.
66. Hayward 1996 {published data only} Hayward AR, Buda K, Jones M, White CJ, Levin MJ. Varicella zoster virus-specific cytotoxicity following secondary immunization with live or killed vaccine. Viral Immunology 1996;9(4):241-5.
67. Heller 1985 {published data only} Heller L, Berglund G, Ahstrom L, Hellstrand K, Wahren B. Early results of a trial of the Oka-strain varicella vaccine in children with leukaemia or other malignancies in Sweden. Postgraduate Medical Journal 1985;61(Suppl 4):79-83.
68. Hesley 2004 {published data only} Hesley TM, Reisinger KS, Sullivan BJ, Jensen EH, Stasiorowski S, Meechan C, et al.Concomitant administration of a bivalent Haemophilus influenzae type b-hepatitis B vaccine, measles-mumps-rubella vaccine and varicella vaccine: safety, tolerability and immunogenicity. Pediatric Infectious Disease Journal 2004;23:240- 5.
69. Horiuchi 1984 {published data only} Horiuchi K. Chickenpox vaccination of healthy children: immunological and clinical responses and protective effect in 1978-1982. Biken Journal 1984;27(2-3):37-8.
70. Iovlev 1969 {published data only} Iovlev VI, Boichuk LM, Kuz'micheva AT, Ivanova MV, Smorodintsev AA. Reactogenic and immunogenic properties of an attenuated strain of chicken pox virus. Voprosy Neirokhirurgii 1969;33(5):561-5.
71. Iwaza 1977 {published data only} Izawa T, Ihara T, Hattori A, Iwasa T, Kamiya H, Sakurai M, et al.Application of a live varicella vaccine in children with acute leukemia or other malignant diseases. Pediatrics 1977;60(6):805-9.
72. Johnson 1988 {published data only} Johnson CE, Shurin PA, Fattlar D, Rome LP, Kumar ML. Live attenuated varicella vaccine in healthy 12- to 24-month-old children. Pediatrics 1988;81(4):512-8.
73. Johnson 1989 {published data only} Johnson C, Rome LP, Stancin T, Kumar ML. Humoral immunity and clinical reinfections following varicella vaccine in healthy children. Pediatrics 1989;84(3):418- 21.
74. Just 1985 {published data only} Just M, Berger R, Luescher D. Live varicella vaccine in healthy individuals. Postgraduate Medical Journal 1985;61(Suppl 4):129-32.
75. Just 1986 {published data only} Just M, Berger R, Just V. Evaluation of a combined measles-mumps-rubella-chickenpox vaccine. Developments in Biological Standardization 1986;65:85-8.
76. Kanra 2000 {published data only} Kanra G, Ceyhan M, Ozmert E. Safety and immunogenicity of live attenuated varicella vaccine in 9-month-old children. Pediatrics International 2000;42(6):674-7.
77. Katsushima 1982 {published data only} Katsushima N, Yazaki N, Sakamoto M, Fujiyama J, Nakagawa M, Okuyama Y, et al.Application of a live varicella vaccine to hospitalized children and its follow-up study. Biken Journal 1982;25(1):29-42.
78. Katsushima 1984 {published data only} Katsushima N, Yazaki N, Sakamoto M. Effect and follow-up study on varicella vaccine. Biken Journal 1984;27(2-3):51-8.
79. Knuf 2006 {published data only} Knuf M, Habermehl P, Zepp F, Mannhardt W, Kuttnig M, Muttonen P, et al.Immunogenicity and safety of two doses of tetravalent measles-mumps- rubella-varicella vaccine in healthy children. Pediatric Infectious Disease Journal 2006;25(1):12-8.
80. Konno 1984 {published data only} Konno T, Yamaguchi Y, Minegishi M, Goto Y, Tsuchiya S. A clinical trial of live attenuated varicella vaccine (Biken) in children with malignant diseases. Biken Journal 1984;27(2-3):73-5.
81. Kosuwon 2004 {published data only} Kosuwon P, Sutra S, Kosalaraksa P. Advantage of a two-dose versus one-dose varicella vaccine in healthy non-immune teenagers and young adults. Southeast Asian Journal of Tropical Medicine & Public Health 2004;35(3):697-701.
82. Krah 1997 {published data only} Krah DL, Cho I, Schofield T, Ellis RW. Comparison of gpELISA and neutralizing antibody responses to Oka/Merck live varicella vaccine (Varivax) in children and adults. Vaccine 1997;15(1):61-4.
83. Krause 1995 {published data only} Krause PR, Klinman DM. Efficacy, immunogenicity, safety, and use of live attenuated chickenpox vaccine. Journal of Pediatrics 1995;127:518-25.
84. Kreth 1994 {published data only} Kreth HW, Prager J, Raue W, Sitzmann FC, Stehr K, Stuck B, et al.Double-blind randomised study on the immunogenicity and reactogenicity of three different selections with two different virus titers each of a newly formulated attenuated Varicella vaccine (Okaphylum) [trans]. Monatsschrift fur Kinderheilkunde 1994;142(Suppl):143.
85. Kreth 2006 {published data only} Kreth HW, Hoeger PH, The Members of the VZV-AD study group. Safety, reactogenicity, and immunogenicity of live attenuated varicella vaccine in children between 1 and 9 years of age with atopic dermatitis. European Journal of Pediatrics 2006;165(10): 677-83.
86. Kumagai 1980 {published data only} Kumagai T, Chiba Y, Fujiwara M, Hanazono H, Nakamura S, Chiba S, et al.Humoral and cellular immune response to varicella-zoster virus in children inoculated with live attenuated varicella vaccine. Biken Journal 1980;23(3):135-41.
87. Kuter 1991 {published data only} Kuter BJ, Weibel RE, Guess HA, et al.Oka/Merck varicella vaccine in healthy children: final report of 2 year efficacy study and 7 year follow up studies. Vaccine 1991;9:643-7.
88. Kuter 1995 {published data only} Kuter BJ, Ngai A, Patterson CM, Staehle BO, Cho I, Matthews H, et al.Safety, tolerability, and immunogenicity of two regimens of Oka/Merck varicella vaccine (Varivax) in healthy adolescents and adults. Oka/Merck Varicella Vaccine Study Group. Vaccine 1995;13:967-72.
89. Kuter 2004 {published data only} Kuter B, Matthews H, Shinefield H, Black S, Dennehy P, Watson B, et al.Ten year follow-up of healthy children who received one or two injections of varicella vaccine. Pediatric Infectious Disease Journal 2004;23:132-7.
90. Kuter 2006 {published data only} Kuter BJ, Brown ML, Hartzel J, Williams WR, EvesiKaren A, Black S, et al.Safety and immunogenicity of a combination measles, mumps, rubella and varicella vaccine (ProQuad). Human Vaccines 2006;2(5):205-14.
91. Lau 2002 {published data only} Lau YL, Vessey SJ, Chan IS, Lee TL, Huang LM, Lee CY, et al.A comparison of safety, tolerability and immunogenicity of Oka/Merck varicella vaccine and VARILRIX in healthy children. Vaccine 2002;20:2942-9.
92. Lawrence 1988 {published data only} Lawrence R, Gershon AA, Holzman R, Steinberg SP. The risk of zoster after varicella vaccination in children with leukemia. New England Journal of Medicine 1988;318:543-8.
93. Leung 2004 {published data only} Leung TF, Li CK, Hung EC, Chan PK, Mo CW, Wong RP, et al.Immunogenicity of a two-dose regime of varicella vaccine in children with cancers. European Journal of Haematology 2004;72:353-7.
94. Levin 1992 {published data only} Levin MJ, Murray M, Rotbart HA, Zerbe GO, White CJ, Hayward AR. Immune response of elderly individuals to a live attenuated varicella vaccine. Journal of Infectious Diseases 1992;166:253-9.
95. Levin 2000 {published data only} Levin MJ, Ellison MC, Zerbe GO, Barber D, Chan C, Stinson D, et al.Comparison of a live attenuated and an inactivated varicella vaccine to boost the varicella-specific immune response in seropositive people 55 years of age and older. Vaccine 2000;18(25):2915-20.
96. Levin 2001 {published data only} Levin MJ, Gershon AA, Weinberg A, Blanchard S, Nowak B, Palumbo P, et al.Immunization of HIV-infected children with varicella vaccine. Journal of Pediatrics 2001;139:305-10.
97. Levin 2003 {published data only} Levin MJ, Smith JG, Kaufhold RM, Barber D, Hayward AR, Chan CY, et al.Decline in varicella-zoster virus (VZV)-specific cell-mediated immunity with increasing age and boosting with a high-hose VZV vaccine. Journal of Infectious Diseases 2003;188:1336-44.
98. Lieberman 2006 {published data only} Lieberman JM, Williams WR, Miller JM, Black S, Shinefield H, Henderson F, et al.The safety and immunogenicity of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children: a study of manufacturing consistency and persistence of antibody. Pediatric Infectious Disease Journal 2006;25(7):615-22.
99. Lim 1998 {published data only} Lim YJ, Chew FT, Tan AY, Lee BW. Risk factors for breakthrough varicella in healthy children. Archives of Disease in Childhood 1998;79:478-80.
100. Lin 1981 {published data only} Lin TY, Wang YM, Lin ST. Application of a live varicella vaccine in children with acute leukemia or nephrotic syndrome. Taiwan i Hsueh Hui Tsa Chih - Journal of the Formosan Medical Association 1981;80:683-90.
101. Lou 1996 {published data only} Lou J, Tan AM, Tan CK. Experience of varicella vaccination in acute lymphoplastic leukaemia. Singapore Medical Journal 1996;37(6):607-10.
102. Lu 1998 {published data only} Lu MY, Huang LM, Lee CY, Lee PI, Chiu HH, Tsai HY. Evaluation of a live attenuated varicella vaccine in 15- to 18-month-old healthy children. Chung-Hua Min Kuo Hsiao Erh Ko i Hsueh Hui Tsa Chih 1998;39:38-42.
103. Macaladad 2007 {published data only} Macaladad N, Marcano T, Guzman M, Moya J, Jurado F, Thompson M, et al.Safety and immunogenicity of a zoster vaccine in varicella-zoster virus seronegative and low-seropositive healthy adults. Vaccine 2007;25(11):2139-44.
104. Meurice 1996 {published data only} Meurice F, De Bouver JL, Vandevoorde D, Woods S, Bogaerts H. Immunogenicity and safety of a live attenuated varicella vaccine (Oka/SB Bio) in healthy children. Journal of Infectious Diseases 1996;174(Suppl 3):324-9.
105. Morales 2000 {published data only} Morales-Castillo ME, Alvarez-Munoz MT, Solorzano-Santos F, Gonzalez-Robledo R, Jasso-Gutierrez L, Munoz-Hernandez O. Live varicella vaccine in both immunocompromised and healthy children. Archives of Medical Research 2000;31:85-7.
106. Nader 1995 {published data only} Nader S, Bergen R, Sharp M, Arvin AM. Age-related differences in cell-mediated immunity to varicella-zoster virus among children and adults immunized with live attenuated varicella vaccine. Journal of Infectious Diseases 1995;171:13-7.
107. Naganuma 1984 {published data only} Naganuma Y, Osawa S, Takahashi R. Clinical application of a live varicella vaccine (Oka strain) in a hospital. Biken Journal 1984;27:59-61.
108. Ndumbe 1985 {published data only} Ndumbe PM, Cradock-Watson JE, Macqueen S, Dunn H, Holzel H, Andre F, et al.Immunisation of nurses with a live varicella vaccine. Lancet 1985;1(8438):1144-7.
109. Neff 1981 {published data only} Neff BJ, Weibel RE, Villarejos VM, Buynak EB, McLean AA, Morton DH, et al.Clinical and laboratory studies of KMcC strain live attenuated varicella virus. Proceedings of the Society for Experimental Biology & Medicine 1981;166(3):339-47.
110. Ngai 1996 {published data only} Ngai AL, Staehle BO, Kuter BJ, Cyanovich NM, Cho I, Matthews H, et al.Safety and immunogenicity of one vs. two injections of Oka/Merck varicella vaccine in healthy children. Pediatric Infectious Disease Journal 1996;15:49-54.
111. Nithichaiyo 2001 {published data only} Nithichaiyo C, Chongsrisawat V, Hutagalung Y, Bock HL, Poovorawa Y. Immunogenicity and adverse effects of live attenuated varicella vaccine (Oka-strain) in children with chronic liver disease. Asian Pacific Journal of Allergy & Immunology 2001;19(2):101-5.
112. Nolan 2002 {published data only} Nolan T, McIntyre P, Roberton D, Descamps D. Reactogenicity and immunogenicity of a live attenuated tetravalent measles-mumps-rubella-varicella (MMRV) vaccine. Vaccine 2002;21:281-9.
113. Oxman 2005 {published data only} Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, et al.A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. New England Journal of Medicine 2005;352(22):2271-84.
114. Ozaki 1978 {published data only} Ozaki T, Nagayoshi S, Morishima T, Isomura S, Suzuki S, Asano Y, et al.Use of a live varicella vaccine for acute leukemic children shortly after exposure in a children's ward. Biken Journal 1978;21(2):69-72.
115. Ozaki 1984 {published data only} Ozaki T, Matsui T, Ichikawa T, Asano Y, Yamanishi K, Takahashi M. Clinical trial of the Oka strain of live attenuated varicella vaccine on healthy children. Biken Journal 1984;27:39-42.
116. Parment 2003 {published data only} Parment PA, Svahn A, Ruden U, Brakenhielm G, Storsaeter J, Akesson L, et al.Immunogenicity and reactogenicity of a single dose of live attenuated varicella vaccine and a booster dose of measles-mumps-rubella vaccine given concomitantly at 12 years of age. Scandinavian Journal of Infectious Diseases 2003;35(10):736- 42.
117. Quien 1977 {published data only} Quien RM, Kaiser BA, Deforest A, Polinsky MS, Fisher M, Baluarte HJ. Response to the varicella vaccine in children with nephrotic syndrome. Journal of Pediatrics 1997;131:688-90.
118. Ramkissoon 1995 {published data only} Ramkissoon A, Coovadia HM, Jugnundan P, Haffejee IE, Meurice F, Vandevoorde D. Immunogenicity and safety of a live attenuated varicella vaccine in healthy Indian children aged 9-24 months. South African Medical Journal 1995;85:1295-8.
119. Redman 1997 {published data only} Redman RL, Nader S, Zerboni L, Liu C, Wong RM, Brown BW, et al.Early reconstitution of immunity and decreased severity of herpes zoster in bone marrow transplant recipients immunized with inactivated varicella vaccine. Journal of Infectious Diseases 1997;176:578-85.
120. Reisinger 2006 {published data only} Reisinger KS, Brown ML, Xu J, Sullivan BJ, Marshall GS, Nauert B, et al.A combination measles, mumps, rubella, and varicella vaccine (ProQuad) given to 4- to 6-year-old healthy children vaccinated previously with M-M-RII and Varivax [Erratum appears in Pediatrics. 2006 Jun;117(6):2338]. Pediatrics 2006;117(2):265- 72.
121. Reuman 1997 {published data only} Reuman PD, Sawyer MH, Kuter BJ, Matthews H. Safety and immunogenicity of concurrent administration of measles-mumps-rubella-varicella vaccine and PedvaxHIB vaccines in healthy children twelve to eighteen months old. The MMRV Study Group. Pediatric Infectious Disease Journal 1997;16:662-7.
122. Ross 1997 {published data only} Ross RT, Nicolle LE, Cheang M. The varicella zoster virus: a pilot trial of a potential therapeutic agent in multiple sclerosis. Journal of Clinical Epidemiology 1997;50:63-8.
123. Rothstein 1997 {published data only} Rothstein EP, Bernstein HH, Ngai AL, Cho I, White CJ. Dose titration study of live attenuated varicella vaccine in healthy children. Pennridge Pediatric Associates. Journal of Infectious Diseases 1997;175:444-7.
124. Saiman 2001 {published data only} Saiman L, LaRussa P, Steinberg SP, Zhou J, Baron K, Whittier S, et al.Persistence of immunity to varicella-zoster virus after vaccination of healthcare workers. Infection Control & Hospital Epidemiology 2001;22:279-83.
125. Salzman 1998 {published data only} Salzman MB, Garcia C. Postexposure varicella vaccination in siblings of children with active varicella. Pediatric Infectious Disease Journal 1998;17:256-7.
126. Sharp 1992 {published data only} Sharp M, Terada K, Wilson A, Nader S, Kinchington PE, Ruyechan WT, et al.Kinetics and viral protein specificity of the cytotoxic T lymphocyte response in healthy adults immunized with live attenuated varicella vaccine. Journal of Infectious Diseases 1992;165:852-8.
127. Shinefield 1998 {published data only} Shinefield HR, Black SB, Staehle BO, Adelman T, Ensor K, Ngai A, et al.Safety, tolerability and immunogenicity of concomitant injections in separate locations of M-M-R II, VARIVAX and TETRAMUNE in healthy children vs. concomitant injections of M-M-R II and TETRAMUNE followed six weeks later by VARIVAX. Pediatric Infectious Disease Journal 1998;17(11):980-5.
128. Shinefield 2002 {published data only} Shinefield HR, Black SB, Staehle BO, Matthews H, Adelman T, Ensor K, et al.Vaccination with measles, mumps and rubella vaccine and varicella vaccine: safety, tolerability, immunogenicity, persistence of antibody and duration of protection against varicella in healthy children. Pediatric Infectious Disease Journal 2002;21:555-61.
129. Shinefield 2005a {published data only} Shinefield H, Black S, Digilio L, Reisinger K, Blatter M, Gress JO, et al.Evaluation of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children. Pediatric Infectious Disease Journal 2005;24(8):665-9.
130. Shinefield 2005b {published data only} Shinefield H, Black S, Williams WR, Marchant C, Reisinger K, Stewart T, et al.Dose-response study of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children [Erratum appears in Pediatr Infect Dis J. 2005 Nov;24(11):983]. Pediatric Infectious Disease Journal 2005;24(8):670-5.
131. Shinefield 2006 {published data only} Shinefield H, Black S, Thear M, Coury D, Reisinger K, Rothstein E, et al.Safety and immunogenicity of a measles, mumps, rubella and varicella vaccine given with combined Haemophilus influenzae type b conjugate/hepatitis B vaccines and combined diphtheria-tetanus-acellular pertussis vaccines. Pediatric Infectious Disease Journal 2006;25(4):287-92.
132. Smith 2003 {published data only} Smith JG, Levin M, Vessey R, Chan IS, Hayward AR, Liu X, et al.Measurement of cell-mediated immunity with a Varicella-Zoster Virus-specific interferon-gamma ELISPOT assay: responses in an elderly population receiving a booster immunization. Journal of Medical Virology 2003;70(Suppl 1):38-41.
133. Sperber 1992 {published data only} Sperber SJ, Smith BV, Hayden FG. Serologic response and reactogenicity to booster immunization of healthy seropositive adults with live or inactivated varicella vaccine. Antiviral Research 1992;17:213-22.
134. Stuck 2002 {published data only} Stuck B, Stehr K, Bock HL. Concomitant administration of varicella vaccine with combined measles, mumps, and rubella vaccine in healthy children aged 12 to 24 months of age. Asian Pacific Journal of Allergy & Immunology 2002;20:113-20.
135. Takahashi 1974 {published data only} Takahashi M, Otsuka T, Okuno Y, Asano Y, Yazaki T. Live vaccine used to prevent the spread of varicella in children in hospital. Lancet 1974;2(7892):1288-90.
136. Takahashi 1985 {published data only} Takahashi M, Kamiya H, Baba K, Asano Y, Ozaki T, Horiuchi K. Clinical experience with Oka live varicella vaccine in Japan. Postgraduate Medical Journal 1985;61(Suppl 4):61-7.
137. Takahashi 2001 {published data only} Takahashi M. 25 years' experience with the Biken Oka strain varicella vaccine: a clinical overview. Paediatric Drugs 2001;3:285-92.
138. Takahashi 2003 {published data only} Takahashi M, Okada S, Miyagawa H, Amo K, Yoshikawa K, Asada H, et al.Enhancement of immunity against VZV by giving live varicella vaccine to the elderly assessed by VZV skin test and IAHA, gpELISA antibody assay. Vaccine 2003;21:3845-53.
139. Takayama 1992 {published data only} Takayama N, Kidokoro M, Suzuki K, Morita M. Immunization of healthy children with measles-mumps-rubella trivalent vaccine simultaneously given with varicella vaccine. Kansenshogaku Zasshi - Journal of the Japanese Association for Infectious Diseases 1992;66(6):776-80.
140. Tan 1996 {published data only} * Tan AY, Connett CJ, Connett GJ, Quek SC, Yap HK, Meurice F, et al.Use of a reformulated Oka strain varicella vaccine (SmithKline Beecham Biologicals/Oka) in healthy children. European Journal of Pediatrics 1996;155:706-11.
141. Terada 2002 {published data only} Terada K, Niizuma T, Ogita S, Kataoka N. Responses of varicella zoster virus (VZV)-specific immunity in seropositive adults after inhalation of inactivated or live attenuated varicella vaccine. Vaccine 2002;20(31-2):3638-43.
142. Trannoy 2000 {published data only} Trannoy E, Berger R, Hollander G, Bailleux F, Heimendinger P, Vuillier D, et al.Vaccination of immunocompetent elderly subjects with a live attenuate Oka strain of varicella zoster virus: a randomized, controlled, dose-response trial. Vaccine 2000;18:1700-6.
143. Ueda 1977 {published data only} Ueda K, Yamada I, Goto M, Nanri T, Fukuda H, Katsuta M, et al.Use of a live varicella vaccine to prevent the spread of varicella in handicapped or immunosuppressed children including MCLS (muco-cutaneous lymphnode syndrome) patients in hospitals. Biken Journal 1977;20(3-4):117-23.
144. Varis 1996 {published data only} Varis T, Vesikari T. Efficacy of high-titer live attenuated varicella vaccine in healthy young children. Journal of Infectious Diseases 1996;174(Suppl 3):330-4.
145. Vazquez 2004 {published data only} Vazquez M, LaRussa PS, Gershon AA, Niccolai LM, Muehlenbein CE, Steinberg SP, et al.Effectiveness over time of varicella vaccine. JAMA 2004;291(7):851-5.
146. Vesikari 1991 {published data only} Vesikari T, Ohrling A, Baer M, Delem A, Bogaerts H, Andre FE. Evaluation of live attenuated varicella vaccine (Oka-RIT strain) and combined varicella and MMR vaccination in 13-17-month-old children. Acta Paediatrica Scandinavica 1991;80:1051-7.
147. Vesikari 2007 {published data only} Vesikari T, Baer M, Willems P. Immunogenicity and safety of a second dose of measles-mumps-rubella- varicella vaccine in healthy children aged 5 to 6 years. Pediatric Infectious Disease Journal 2007;26(2):153-8.
148. Vessey 2001 {published data only} Vessey SJ, Chan CY, Kuter BJ, Kaplan KM, Waters M, Kutzler DP, et al.Childhood vaccination against varicella: persistence of antibody, duration of protection, and vaccine efficacy. Journal of Pediatrics 2001;139:297-304.
149. Watson 1993a {published data only} Watson B, Piercy S, Soppas D, Browngoehl K, Warner M, Isganitis K, et al.The effect of decreasing amounts of live virus, while antigen content remains constant, on immunogenicity of Oka/Merck varicella vaccine. Journal of Infectious Diseases 1993;168:1356-60.
150. Watson 1993b {published data only} Watson BM, Piercy SA, Plotkin SA, Starr SE. Modified chickenpox in children immunized with the Oka/Merck varicella vaccine. Pediatrics 1993;91:17-22.
151. Watson 1994 {published data only} Watson B, Gupta R, Randall T, Starr S. Persistence of cell-mediated and humoral immune responses in healthy children immunized with live attenuated varicella vaccine. Journal of Infectious Diseases 1994;169(1):197-9.
152. Watson 1995 {published data only} Watson B, Boardman C, Laufer D, Piercy S, Tustin N, Olaleye D, et al.Humoral and cell-mediated immune responses in healthy children after one or two doses of varicella vaccine. Clinical Infectious Diseases 1995;20:316-9.
153. Watson 1996 {published data only} Watson BM, Laufer DS, Kuter BJ, Staehle B, White CJ, Starr SE. Safety and immunogenicity of a combined live attenuated measles, mumps, rubella, and varicella vaccine (MMR(II)V) in healthy children [Erratum appears in J Infect Dis 1996 Jun;173(6):1529]. Journal of Infectious Diseases 1996;173(3):731-4.
154. Watson 2000 {published data only} Watson B, Seward J, Yang A, Witte P, Lutz J, Chan C, et al.Postexposure effectiveness of varicella vaccine. Pediatrics 2000;105:84-8.
155. Webb 2000 {published data only} Webb NJ, Fitzpatrick MM, Hughes DA, Brocklebank TJ, Judd BA, Lewis MA, et al.Immunisation against varicella in end stage and pre-end stage renal failure. Trans-Pennine Paediatric Nephrology Study Group. Archives of Disease in Childhood 2000;82:141-3.
156. Weibel 1984 {published data only} Weibel RE, Neff BJ, Kuter BJ, Guess HA, Rothenberger CA, Fitzgerald AJ, et al.Live attenuated varicella virus vaccine. Efficacy trial in healthy children. New England Journal of Medicine 1984;310:1409-15.
157. Weibel 1985 {published data only} Weibel RE, Kuter BJ, Neff BJ, Rothenberger CA, Fitzgerald AJ, Connor KA, et al.Live Oka/Merck varicella vaccine in healthy children. Further clinical and laboratory assessment. JAMA 1985;254:2435-9.
158. White 1991 {published data only} White CJ, Kuter BJ, Hildebrand CS, Isganitis KL, Matthews H, Miller WJ, et al.Varicella vaccine (VARIVAX) in healthy children and adolescents: results from clinical trials, 1987 to 1989. Pediatrics 1991;87:604-10.
159. White 1992 {published data only} White CJ, Kuter BJ, Ngai A, Hildebrand CS, Isganitis KL, Patterson CM, et al.Modified cases of chickenpox after varicella vaccination: correlation of protection with antibody response. Pediatric Infectious Disease Journal 1992;11:19-23.
160. White 1997 {published data only} White CJ. Varicella-zoster virus vaccine. Clinical Infectious Diseases 1997;24:753-61.
161. Wise 2000 {published data only} Wise RP, Salive ME, Braun MM, Mootrey GT, Seward JF, Rider LG, et al.Postlicensure safety surveillance for varicella vaccine [Erratum appears in JAMA 2000 Dec 27;284(24):3129]. JAMA 2000;284:1271-9.
162. Yerkovich 2007 {published data only} Yerkovich ST, Rowe J, Richmond P, Suriyaarachchi D, Heaton T, Hollams E, et al.Assessment of the potency and potential immunomodulatory effects of the measles mumps rubella and varicella vaccine in infants. Vaccine 2007;25(10):1764-70.
163. Yeung 1992 {published data only} Yeung CY, Liang DC. Varicella vaccine in children with acute lymphoblastic leukemia and non-Hodgkin lymphoma. Pediatric Hematology & Oncology 1992;9:29-34.
164. Zerboni 1998 {published data only} Zerboni L, Nader S, Aoki K, Arvin AM. Analysis of the persistence of humoral and cellular immunity in children and adults immunized with varicella vaccine. Journal of Infectious Diseases 1998;177:1701-4.
165. Black 1999 Black S, Shinefield H, Ray P, Lewis E, Hansen J, Schwalbe J, et al.Postmarketing evaluation of the safety and effectiveness of varicella vaccine. Pediatric Infectious Disease Journal 1999;18(12):1041-6.
166. Breuer 2001 Breuer J. Vaccination to prevent varicella and shingles. Journal of Clinical Pathology 2001;54(10):743-7.
167. Enders 1994 Enders G, Miller E, Cradock-Watson J, Bolley I, Ridehalgh M. Consequences of varicella and herpes zoster in pregnancy: prospective study of 1739 cases. Lancet 1994;343(8912):1548-51.
168. Ferson 2001 Ferson MJ. Varicella vaccine in post-exposure prophylaxis. Communicable Diseases Intelligence 2001;25:13-5.
169. Gershon 2004 Gershon AA, Takahashi M, Seward J. Varicella vaccine. In: Plotkin SA, Orenstein WA editor(s). Vaccines. 4th Edition. Philadelphia, PA: Saunders, 2004:783-824.
170. Gnann 2002 Gnann JW, Jr, Whitley RJ. Clinical practice. Herpes zoster. New England Journal of Medicine 2002;347(5):340-6.
171. Guess 1986 Guess HA, Broughton DD, Melton LJ, III, Kurland LT. Population-based studies of varicella complications. Pediatrics 1986;78(4 Pt 2):723-7.
172. Hambleton 2005 Hambleton S, Gershon AA. Preventing varicella-zoster disease. Clinical Microbiology Reviews 2005;18(1):70-80.
173. Higgins 2005 Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]. In: The Cochrane Library, Issue 3. Chichester, UK: John Wiley & Sons, Ltd, 2005.
174. Kesson 1996 Kesson AM, Grimwood K, Burgess MA, Ferson MJ, Gilbert GL, Hogg G, et al.Acyclovir for the prevention and treatment of varicella zoster in children, adolescents and pregnancy. Journal of Paediatrics and Child Health 1996;32(3):211-7.
175. Macartney 2005 Macartney KK, Beutels P, McIntyre P, Burgess MA. Varicella vaccination in Australia. Journal of Paediatrics and Child Health 2005;41(11):544-52.
176. Marin 2007 Marin M, Guris D, Chaves SS, Schmid S, Seward JF, Advisory Committee on Immunization Practices CfDCaPC. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbidity and Mortality Weekly Report 2007;56(RR-4):1-40.
177. MMWR 1996 MMWR. Prevention of varicella: Recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbidity and Mortality Weekly Report 1996;45(RR-11):1-36.
178. NACI 2004 National Advisory Committee on Immunization (NACI). National Advisory Committee on Immunization (NACI) update on varicella. Canada Communicable Disease Report 2004;30:1-26.
179. NHMRC 2008 National Health and Medical Research Council. The Australian Immunisation Handbook. 9th Edition. Australian Government, 2008. [: ISBN 1-74186-483-6]
180. Ogilvie 1998 Ogilvie MM. Antiviral prophylaxis and treatment in chickenpox. A review prepared for the UK Advisory Group on Chickenpox on behalf of the British Society for the Study of Infection. Journal of Infection 1998;36(Suppl 1):31-8.
181. Pastuszac 1994 Pastuszac AL, Levy M, Schick B, et al.Outcome after maternal varicella infection in the first 20 weeks of pregnancy. New England Journal of Medicine 1994;330:901-5.
182. Preblud 1984 Preblud SR, Orenstein WA, Bart KJ, et al.Varicella: clinical manifestations, epidemiology and health impact in children. Pediatric Infectious Disease Journal 1984;3:505-9.
183. Sharrar 2000 Sharrar RG, LaRussa P, Galea SA, Steinberg SP, Sweet AR, Keatley RM, et al.The postmarketing safety profile of varicella vaccine. Vaccine 2000;19(7-8):916-23.
184. Simpson 1952 Simpson REH. Infectiousness of communicable diseases in the household (measles, chickenpox, and mumps). Lancet 1952;ii:549-54.
185. Skull 2001 Skull SA, Wang EE. Varicella vaccination - a critical review of the evidence. Archives of Disease in Childhood 2001;85(2):83-90.
186. Takahashi 1996 Takahashi M. The varicella vaccine. Vaccine development. Infectious Disease Clinics of North America 1996;10(3):469-88.